Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Plby Group Inc (PLBY) Price & Performance

Cassava Sciences IncTrade
Plby Group IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Plby Group Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Plby Group Inc trades at $1.22 (market cap $162.94M). The key difference: Plby Group Inc is far larger — about 3.4× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.

FLNAPLBY
Market Cap
$47.75M$162.94M
Sector
HealthConsumer Cyclical
52-Week High
$4.64$2.71
52-Week Low
$0.87$1.11
Enterprise Value
-$34.93M$308.52M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Plby Group Inc

PLBY Group trades at $1.255, up 6.36% with bullish technical signals from moving averages. The company shows improving fundamentals with Q2 2026 revenue growth and a return to operating profitability, while net income margin remains thin at 0.23%. Recent developments include inclusion in Russell indexes and strategic share repurchases. Analyst consensus is strongly positive with 75% buy ratings.

The outlook suggests gradual recovery with projected 2026 profitability, though high P/E of 68 and negative shareholder equity pose valuation concerns. Key opportunities include licensing growth and brand expansion, while risks involve debt burden and competitive pressures in the leisure sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Plby Group Inc

PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.

Read more on PLBY